Background illustration for clinical trials search

Gene Therapy Clinical Trials

Find clinical trials for gene therapy. Search for gene therapy clinical trials in different cities and states across the United States.

Filter

Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients

for
Small Cell Lung Cancer Extensive Stage
Location: Fairfax VA, Canton OH, Cincinnati OH, Fairfield OH,
Sponsor: Genprex, Inc.

Sex: All

Age: 18+

Code: NCT05703971

Phase1, Phase2, Recruiting

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

for
Carcinoma, Non-Small-Cell Lung
Location: New York NY
Sponsor: Weill Medical College of Cornell University

Sex: All

Age: 18+

Code: NCT06623656

Phase2, Recruiting

Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy

for
Neoplasm, Colorectal, Cognitive Impairment,
Location: Fort Wayne IN
Sponsor: Joseph McCollom

Sex: All

Age: 18+

Code: NCT05014399

Recruiting

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

for
Langerhans Cell Histiocytosis
Location: Allentown PA, Norfolk VA, Columbus OH, Houston TX,
Sponsor: Baylor College of Medicine

Sex: All

Age: 0 - 21

Code: NCT02670707

Phase3, Recruiting

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

for
Head and Neck Squamous Cell Carcinoma,
Location: Weston WI, Bremerton WA
Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All

Age: 18+

Code: NCT02734537

Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

for
Embryonal Rhabdomyosarcoma,
Location: Halifax, Scarborough ME, Boston MA, Providence RI,
Sponsor: Children's Oncology Group

Sex: All

Age: 0 - 21

Code: NCT05304585

Phase3, Recruiting

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors

for
Advanced Solid Tumor,
Location: Boston MA, Lebanon NH, Morristown NJ,
Sponsor: Vaxiion Therapeutics

Sex: All

Age: 18+

Code: NCT05901285

Phase1, Recruiting

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

for
NHL, Multiple Myeloma, Blood Cancer,
Location: Providence RI, Fairfax VA, Winston-Salem NC,
Sponsor: Indapta Therapeutics, INC.

Sex: All

Age: 18+

Code: NCT06119685

Phase1, Phase2, Recruiting

Prism Adaptation Therapy (PAT) for Right Brain Stroke Rehabilitation

for
Spatial Neglect After Right Brain Stroke
Location: West Haven CT, Leeds MA, Cleveland OH, Decatur GA
Sponsor: VA Office of Research and Development

Sex: All

Age: 18+

Code: NCT05983185

Recruiting

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

for
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma,
Location: Saint Johnsbury VT, Lebanon NH, New York NY,
Sponsor: SWOG Cancer Research Network

Sex: All

Age: 18+

Code: NCT05633615

Phase2, Recruiting

Healthy Recovery After Trauma Study

for
Stress Disorders, Post-Traumatic, Shame, Guilt,
Location: Lexington KY
Sponsor: Christal L Badour

Sex: All

Age: 18+

Code: NCT04585685

Recruiting

Co-administration of CART22-65s and huCART19 for B-ALL

for
B-cell Acute Lymphoblastic Leukemia,
Location: Philadelphia PA
Sponsor: Stephan Grupp MD PhD

Sex: All

Age: 0 - 29

Code: NCT05674175

Phase1, Phase2, Recruiting

MDMA for Co-occurring PTSD and OUD After Childbirth

for
Stress Disorders, Post-Traumatic, Opioid Use Disorder
Location: Albuquerque NM
Sponsor: University of New Mexico

Sex: Female

Age: 18+

Code: NCT05219175

Phase2, Recruiting

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

for
Merkel Cell Carcinoma
Location: New York NY, Madison WI, Iowa City IA
Sponsor: Weill Medical College of Cornell University

Sex: All

Age: 18+

Code: NCT05583708

Phase2, Recruiting

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

for
Breast Cancer, HER2-positive Breast Cancer
Location: Chicago IL
Sponsor: University of Illinois at Chicago

Sex: All

Age: 18+

Code: NCT06441890

Phase2, Recruiting

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

for
Gastroesophageal-junction Cancer, Monoclonal Antibody,
Location: Sayre PA, West Palm Beach FL, Pompano Beach FL,
Sponsor: Shanghai Henlius Biotech

Sex: All

Age: 18+

Code: NCT06532006

Phase3, Recruiting

Telemedicine-Delivered Unified Protocol for Cognitive Behavioral Therapy for Anxiety and Depression

for
Diabetes, Type 1 Diabetes
Location: Boston MA, The Bronx NY
Sponsor: Albert Einstein College of Medicine

Sex: All

Age: 18 - 64

Code: NCT05734313

Recruiting

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation

for
Pancreatic Acinar Cell Carcinoma,
Location: Saint Johnsbury VT, Lebanon NH, Commack NY,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04858334

Phase2, Recruiting

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

for
B-ALL, Hematologic Malignancy, Solid Tumor
Location: Philadelphia PA, Milwaukee WI, Memphis TN, Aurora CO,
Sponsor: St. Jude Children's Research Hospital

Sex: All

Age: 0 - 30

Code: NCT06579469

Recruiting

Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

for
Diffuse Large B Cell Lymphoma (DLBCL)
Location: Montreal, Toronto
Sponsor: University Health Network, Toronto

Sex: All

Age: 18+

Code: NCT06050694

Phase2, Recruiting

What is gene therapy, and how does it work?

Many diseases come from a single gene that is missing, broken, or overactive. Gene therapy aims to correct that instead of treating the symptoms. There are three main approaches. Gene addition delivers a working copy of the gene, usually inside a harmless modified virus called a vector, most often an adeno associated virus (AAV). Gene silencing turns down a harmful gene. Gene editing, using tools like CRISPR, cuts and repairs the DNA itself. The therapy can be given directly into the body, as an infusion or an injection into the eye or spinal fluid, or done outside it: stem cells are collected, modified in a lab, and returned, which is how sickle cell gene therapies work.

Approved examples show the range. Luxturna (2017) restores some vision in a rare inherited blindness. Zolgensma (2019) treats spinal muscular atrophy in infants with a single infusion. Hemgenix (2022) lets many people with hemophilia B stop regular factor infusions. Casgevy (December 2023) was the first CRISPR based medicine, for sickle cell disease and beta thalassemia. Most trials today are in rare genetic diseases, inherited eye and blood disorders, and neurological conditions, with growing work in more common diseases like heart failure and Parkinson's. Our article on the future of gene therapy in clinical trials goes deeper.

Types of gene therapy clinical trials

How much does gene therapy cost?

Who can participate in gene therapy trials?

Do gene therapy trial participants get paid?

How to enroll in a gene therapy clinical trial